A controlled trial of 5-hydroxy-L-tryptophan for ataxia in progressive myoclonus epilepsy

Clin Neurol Neurosurg. 1996 May;98(2):161-4. doi: 10.1016/0303-8467(96)00014-5.

Abstract

To study the role of serotonin in the ataxia of progressive myoclonus epilepsy, eight patients received oral 5-hydroxy-L-tryptophan (L-5-HTP) or placebo plus carbidopa for 1 month in a controlled, double-blinded, dose-ranging, cross-over, add-on study. Ataxia was evaluated using objective and subjective scales. All of the subjects had significantly slower motor performance on timed, repetitive tasks than controls and had moderately severe ataxia. L-5-HTP was not efficacious for ataxia or speed of motor performance. Serotonergic drugs that work through mechanisms different than L-5-HTP may be more effective in correcting the abnormal serotonergic neurotransmission suggested by reduction of serotonin metabolites in cerebrospinal fluid in patients with progressive myoclonus epilepsy.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 5-Hydroxytryptophan / administration & dosage*
  • Administration, Oral
  • Adolescent
  • Adult
  • Ataxia / complications
  • Ataxia / drug therapy*
  • Double-Blind Method
  • Epilepsies, Myoclonic / complications*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies

Substances

  • 5-Hydroxytryptophan